OncoMatch/Clinical Trials/NCT06680089
CD70-targeted immunoPET Imaging of Kidney Cancer
Is NCT06680089 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies [18F]RCCB6 for urologic neoplasms.
Treatment: [18F]RCCB6 — The aim of this study is to establish and optimize the \[18F\]RCCB6 PET/CT imaging method, and its physiological and pathological distribution characteristics, on the basis of which the diagnostic efficacy of the above imaging agent in renal cancer (especially clear cell renal cell carcinoma) wil be evaluated.
Check if I qualifyEligibility summary
For patients with Renal Cell Carcinoma.
This summary was generated by AI from the trial's official eligibility criteria and may contain errors. Always confirm with the study team before contacting a site.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify